Department of General Surgery, the First People's Hospital of Neijiang, Neijiang, 641000, Sichuan Province, PR China.
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Hainan Medical University, Haikou, 570100, Hainan Province, PR China.
BMC Cancer. 2020 Jun 5;20(1):525. doi: 10.1186/s12885-020-07014-w.
Previous researches have reported that tripartite motif-containing 44 (TRIM44) is related to the prognosis of multiple human tumors. This study was designed to systematically assess the prognostic value of TRIM44 in human malignancies and summarize its possible tumor-related mechanisms.
The available databases were searched for eligible studies that evaluated the clinicopathological and prognostic roles of TRIM44 in patients with malignancies. The hazard ratios (HR) and odds ratios (OR) were combined to assess the predictive role of TRIM44 using Stata/SE 14.1 software.
A total of 1740 patients from thirteen original studies were finally included in this study. The results of the combined analysis showed that over-expression of TRIM44 protein was significantly correlated with shorter overall survival (OS) (HR = 1.94, 95% CI: 1.60-2.35) and worse disease-free survival (DFS) (HR = 2.13, 95% CI: 1.24-3.65) in cancer patients. Additionally, the combined ORs indicated that elevated expression level of TRIM44 protein was significantly associated with lymph node metastasis (OR = 2.69, 95% CI: 1.71-4.24), distant metastasis (OR = 10.35, 95% CI: 1.01-106.24), poor tumor differentiation (OR = 1.78, 95% CI: 1.03-3.09), increased depth of tumor invasion (OR = 2.72, 95% CI: 1.73-4.30), advanced clinical stage (OR = 2.75, 95% CI: 2.04-3.71), and recurrence (OR = 2.30, 95% CI: 1.34-3.95). Furthermore, analysis results using Gene Expression Profiling Interactive Analysis (GEPIA) showed that the expression level of TRIM44 mRNA was higher in most tumor tissues than in the corresponding normal tissues, and the relationship between TRIM44 mRNA level and prognosis in various malignant tumors also explored in GEPIA and OS analysis webservers.
TRIM44 may serve as a valuable prognostic biomarker and a potential therapeutic target for patients with malignancies.
先前的研究表明,三结构域蛋白 44(TRIM44)与多种人类肿瘤的预后有关。本研究旨在系统评估 TRIM44 在人类恶性肿瘤中的预后价值,并总结其可能的肿瘤相关机制。
检索了评估 TRIM44 在恶性肿瘤患者中的临床病理和预后作用的可用数据库。使用 Stata/SE 14.1 软件,通过风险比(HR)和优势比(OR)来组合评估 TRIM44 的预测作用。
最终纳入了来自 13 项原始研究的 1740 名患者。合并分析的结果表明,TRIM44 蛋白的过表达与癌症患者的总生存期(OS)(HR=1.94,95%CI:1.60-2.35)和无病生存期(DFS)(HR=2.13,95%CI:1.24-3.65)更短显著相关。此外,合并 OR 表明,TRIM44 蛋白表达水平升高与淋巴结转移(OR=2.69,95%CI:1.71-4.24)、远处转移(OR=10.35,95%CI:1.01-106.24)、肿瘤分化不良(OR=1.78,95%CI:1.03-3.09)、肿瘤侵袭深度增加(OR=2.72,95%CI:1.73-4.30)、临床分期较晚(OR=2.75,95%CI:2.04-3.71)和复发(OR=2.30,95%CI:1.34-3.95)显著相关。此外,使用基因表达谱分析交互分析(GEPIA)的分析结果表明,TRIM44 mRNA 在大多数肿瘤组织中的表达水平高于相应的正常组织,并且在 GEPIA 和 OS 分析网络服务器中还探讨了 TRIM44 mRNA 水平与各种恶性肿瘤预后的关系。
TRIM44 可能作为恶性肿瘤有价值的预后生物标志物和潜在的治疗靶点。